SEHK:2181

Stock Analysis Report

Executive Summary

Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Mabpharm's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.1%

2181

3.0%

HK Biotechs

0.9%

HK Market


1 Year Return

n/a

2181

1.3%

HK Biotechs

0.6%

HK Market

Return vs Industry: Insufficient data to determine how 2181 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 2181 performed against the Hong Kong Market.


Shareholder returns

2181IndustryMarket
7 Day3.1%3.0%0.9%
30 Day-7.4%2.0%0.5%
90 Day-18.7%-4.1%-4.3%
1 Yearn/a1.8%1.3%4.2%0.6%
3 Yearn/a40.6%37.5%15.6%4.0%
5 Yearn/a41.2%38.6%20.0%-0.08%

Price Volatility Vs. Market

How volatile is Mabpharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mabpharm undervalued compared to its fair value and its price relative to the market?

3.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2181 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2181 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2181's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2181 is overvalued based on its PB Ratio (3.3x) compared to the HK Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Mabpharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mabpharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Mabpharm's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Mabpharm competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Mabpharm performed over the past 5 years?

-173.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if 2181's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).


Return on Equity

High ROE: 2181 has a negative Return on Equity (-19.61%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 2181 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 2181 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Mabpharm's financial position?


Financial Position Analysis

Short Term Liabilities: 2181's short term assets (CN¥1.1B) exceeds its short term liabilities (CN¥231.9M)

Long Term Liabilities: 2181's short term assets (1.1B) exceeds its long term liabilities (41.7M)


Debt to Equity History and Analysis

Debt Level: 2181's debt to equity ratio (8.5%) is considered satisfactory

Reducing Debt: Insufficient data to determine if 2181's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 2181 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2181's debt is covered by short term assets (assets are 11.068430x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2181 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2181 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -35.9% each year


Next Steps

Dividend

What is Mabpharm's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%6.3%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 2181's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2181's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 2181's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2181's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2181's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

What is the CEO of Mabpharm's salary, the management and board of directors tenure and is there insider trading?


CEO

Mabpharm has no CEO, or we have no data on them.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCN¥9,847,19312 Jun 19
China International Capital Corporation Hong Kong Asset Management Limited
EntityCompany
Shares6,890,000
Max PriceCN¥1.43

Ownership Breakdown


Management Team

  • Yunfeng Li

    Executive Director & Chief Financial Officer

    • Tenure: 0yrs

Board Members

  • Yunfeng Li

    Executive Director & Chief Financial Officer

    • Tenure: 0yrs

Company Information

Mabpharm Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mabpharm Limited
  • Ticker: 2181
  • Exchange: SEHK
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$4.165b
  • Shares outstanding: 4.12b
  • Website: https://www.mabpharm.cn

Number of Employees


Location

  • Mabpharm Limited
  • Block G79
  • Lujia Road East
  • Taizhou
  • Zhejiang Province
  • 225300
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2181SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDMay 2019

Biography

Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. The company’s products under  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 12:59
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.